Salarius Announces Allowance of New European Patent Covering Seclidemstat
March 04, 2020 08:00 ET
|
Salarius Pharmaceuticals
European Patent Office Satisfied Patent Application Meets All Requirements Salarius’ Global Intellectual Property Estate Includes 22 Issued Patents in the U.S., Europe and 12 Other Jurisdictions ...
Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference
March 02, 2020 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, March 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today...
Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
February 11, 2020 16:05 ET
|
Salarius Pharmaceuticals
HOUSTON, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Pharmaceuticals to Present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference
February 10, 2020 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced...
Salarius Announces Pricing of $9.6 Million Underwritten Public Offering
February 07, 2020 08:30 ET
|
Salarius Pharmaceuticals
HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of...
Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference
February 05, 2020 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced...
Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors
February 04, 2020 08:00 ET
|
Salarius Pharmaceuticals
Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical Study Data Supports Continued Study of Seclidemstat...
Salarius Pharmaceuticals to Present at Biotech Showcase 2020
December 19, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred...
Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression
December 17, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will...
Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma
December 16, 2019 08:00 ET
|
Salarius Pharmaceuticals
HOUSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced...